“…Through facilitating the activation of WASH, MAGEL2 functions as a tissue-specific regulator of ARP2/3 activation in the hypothalamus ( Hao et al, 2013 ; Hao et al, 2015 ). The loss of MAGEL2 expression causes deficits in SG abundance and bioactive neuropeptide production, impacting hypothalamic neuroendocrine function and contributing to the clinical presentation of PWS ( Figure 6B ) ( Chen et al, 2020 ; Hoyos Sanchez et al, 2023 ). In particular, reduced levels of the neuropeptides vasopressin, galanin, oxytocin, proenkephalin, somatostatin, and thyrotropin-releasing hormone and the SG components involved in their processing and release (i.e., CHGB, secretogranin II and III, PC1/3, PC2, and CPE) have been discovered in PWS mouse models and patient-derived neuronal cell models ( Chen et al, 2020 ; Hoyos Sanchez et al, 2023 ).…”